海南海藥(000566.SZ):捐贈468萬元藥品用於支持新冠病毒肺炎疫情防控
格隆匯2月3日丨海南海藥(000566.SZ)公佈,目前,新型冠狀病毒感染肺炎疫情形勢嚴峻,嚴重威脅着人民羣眾的身體健康和生命安全。公司高度關注疫情發展,將防控疫情放在首位,一方面努力保障適用於呼吸道感染相關藥品的生產,一方面為支持湖北地區抗擊疫情,春節假期期間,公司迅速行動組織所需藥品,於2020年1月26日向湖北省公安廳捐贈了價值人民幣468萬元的藥品。
本次捐贈的藥品頭孢克洛顆粒、頭孢克洛膠囊、阿莫西林膠囊、阿莫西林分散片,主要用於改善發熱、咳嗽等症狀;楓蓼腸胃康顆粒主要用於改善腹痛、腹瀉、噁心、嘔吐症狀或改善糖尿病患者的腹痛、腹瀉、噁心、嘔吐症狀。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.